MediLexicon Logo
MediLexicon Logo
Abbreviations        Abbrev Definitions        Dictionary        ICD9 Codes        Equipment        Hospitals        Drugs        More..
  

Useful Websites

Global Translations
Medical and Clinical Translation

specialistinfo.com
Details of over 40,000 UK Specialists and over 42,000 GPs

Global RPH
medical software

Doctors Lounge
Ask a Doctor and Disease Information

Health News
from Medical News Today.

MRCP 1 Revision
123 Doc medical courses for junior doctors.

CoreyNahman
pharmaceutical news daily

Hospital Search
Worldwide hospital database, search by country or keyword.

Metric Conversions
The Converter Site - unit conversion tool.
headlines news headlines   email email to a friend   printer printer friendly   newsletter sign up to newsletter  

Multiple Adverse Histological Features Increase The Odds Of Under Staging T1 Bladder Cancer

Main Category: Urology / Nephrology
Also Included In: Cancer / Oncology
Article Date: 16 Aug 2009

UroToday.com - Patients with T1 bladder cancer have an uncertain natural history. It is clear that patients who are allowed to progress to muscle invasive disease have similar survival to patients who present initially with muscle invasive disease.

Currently, there are few markers that are available to predict which patients will progress to muscle invasive disease and need earlier, more aggressive intervention.

Time to definitive therapy has been shown to be critical in the survival of patients with invasive bladder cancer. This is important for patients with T1 bladder cancer because the risk of under-staging occurs in up to 30% of patients. While a re-staging transurethral resection can help identify those patients who have been under-staged, we performed the current study to determine other histologic features that may be associated with the risk of under-staging. Invasion of the muscularis mucosae (when present), urethral involvement, and divergent histology all increased the risk of under-staging, and the cumulative effect of having all three adverse features increased the odds of under-staging 20-fold.

While these features do not replace the need for a re-staging transurethral resection of the bladder, their presence on the initial biopsy may guide clinicians to recommend earlier more definitive therapy with T1 disease potentially reducing the timeline to proceed to more aggressive management such as radical cystectomy and urinary diversion.

Written by Alon Z. Weizer, MD as part of Beyond the Abstract on UroToday.com

UroToday - the only urology website with original content written by global urology key opinion leaders actively engaged in clinical practice. To access the latest urology news releases from UroToday, go to: www.urotoday.com

Copyright © 2009 - UroToday

Original article posted on Medical News Today.
Articles not to be reproduced without permission of Medical News Today

Medical News Today publishes the latest health news and health videos for consumers and health professionals. It has a searchable archive of over 100,000 health news articles.





For any corrections of factual information, or to contact the editors please use our feedback form.
Send your press releases to








free web search box


pda medical dictionary
pda software - $15

PDA Medical Dictionary

only $15

Take MediLexicon's abbreviations search with you where-ever you go with our PDA software. As an extra, this software is available with an extra medical dictionary...

>> Click here for more on the PDA Medical Dictionary <<




add to google

Add our searches to your Google homepage.

Add to Google

The 60 seconds challenge: Add these searches to your Google homepage within 60 seconds - simply click here and follow these instructions


Receive the latest medical news on your Google homepage.

Add to Google

The 60 seconds challenge: Receive the latest medical news on your Google homepage within 60 seconds - simply click here and follow these instructions





Privacy Policy   |    Disclaimer      

MediLexicon International Ltd, UK Office: +44 (0) 1625 415 347
MediLexicon International Ltd © 2009 All rights reserved.